Sotyktu (Deucravacitinib)

Sotyktu (deucravacitinib) is a tyrosine kinase 2 (TYK2) inhibitor used for the treatment of adult individuals with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. 

Limitations of Use: This medicinal product is not recommended for use in conjunction with other potent immunosuppressants.

Recommended Dosage: Evaluate individuals for active as well as latent tuberculosis (TB) infection before starting Sotyktu treatment. If positive, initiate treatment for tuberculosis prior to the use of this therapy. Update immunizations as per current immunization guidelines.

The recommended dosage of Sotyktu tablet is 6 mg taken orally once daily, with or without food. Do not chew, crush, or cut the pills. This medicinal product is not recommended for those with severe hepatic impairment (Child-Pugh C).

• Hypersensitivity reactions such as angioedema may occur in subjects receiving Sotyktu therapy. In case of clinically significant hypersensitivity reaction, institute apt therapy and discontinue treatment with Sotyktu.
• Sotyktu may be responsible for increasing the risk of infections. Avoid use of this medication in those with an active or severe infection. Precisely monitor individuals for the development of signs and/or symptoms of infection throughout and after therapy with Sotyktu tablets. 
• Consider anti-TB therapy before initiation of Sotyktu 6 mg tablets in patients with a past history of latent or active TB in whom an apt course of therapy cannot be confirmed. Evaluate patients receiving this treatment for signs and/or symptoms of active TB throughout the treatment. 
• Malignancies, including lymphomas, may occur with Deucravacitinib. Consider the benefits and risks for the individual patient before starting or continuing treatment, particularly those with a known malignancy and those who establish a malignancy when on Deucravacitinib treatment. 
• Before initiating treatment with Deucravacitinib, complete all age-appropriate immunizations as per current immunization guidelines including prophylactic herpes zoster vaccination. Do not use live vaccines in those treated with this medicine. The response to live or non-live vaccines yat to be assessed.

What documents are required to import SOTYKTU to India?

SOTYKTU (deucravacitinib) tablets can be imported by patients or government hospitals in the name of the patients only.

The following documentation is required to import the product:

1. A valid prescription from a qualified doctor.
2. Patient’s diagnostic reports
3. Patient’s ID proof (issued by the government of India)

How does the order be confirmed?

The order will be confirmed only after the receipt of:

1. A valid prescription from the Doctor
2. Import permit if applicable

Is SOTYKTU available in India?

SOTYKTU (deucravacitinib tablets) is a prescription drug that legally requires a medical prescription to be dispensed.

Urgent Meds helps import cancer medicines on the named patient supply (NPS). Urgent Meds provides input on:

• Availability of Sotyktu in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• Medicine Price.
• Finding genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

SOTYKTU can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

Urgent Meds can facilitate the supply of SOTYKTU (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +1-647-818-4196 or write to us at info@urgentmeds.in for Sotyktu 6 mg price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Urgent Meds is proficient in sourcing SOTYKTU (Cancer Treatment Medicines) from around the world and has the capability to supply it. We offer global access to the best available treatment for our customers worldwide.

Urgent Meds is committed to dispensing any valid prescription promptly. All prescriptions are dispensed and verified by registered pharmacists and are dispatched only to the patient’s address from New Delhi, India. Your health and well-being are our top priorities.

What is the Generic Name for the trade name drug Sotyktu®?

Deucravacitinib is the Generic Name for the trade name drug Sotyktu®.

What is the Manufacturer’s Name of Sotyktu®?

Sotyktu® is manufactured by Bristol Myers Squibb.

Is Sotyktu® approved by the FDA?

Yes, Sotyktu® is approved by the FDA. Date of approval: September 9, 2022.

Where can I get Sotyktu® at the best price in India?

To get the best Sotyktu price in India, kindly connect with Urgent Meds (a WHO GDP & ISO 9001:2008 certified company). For Sotyktu®, a medical prescription is required from a treating physician.

What is the dosage and form of Sotyktu® supplied?

Sotyktu® is supplied as Tablets: 6 mg for oral administration.

What are the most commonly reported side effects of Sotyktu®?

The most commonly reported side effects of Sotyktu® are blood creatine phosphokinase increased, acne, herpes simplex, upper respiratory infections, folliculitis, and mouth ulcers.

How much does Sotyktu® cost in India?

The cost of Sotyktu in India can vary. In order to procure this TYK2 inhibitor legally, you can call or WhatsApp +1-647-818-4196 or send mail to info@urgentmeds.in.

What are the storage conditions of Sotyktu®?

Store the tablets of Sotyktu at room temperature between 68 to 77°F (20 to 25°C).

Is it safe to buy Sotyktu® online in India?

Yes, one can buy Sotyktu online in India at the lowest price from Urgent Meds if the medicine Sotyktu® is not (yet) registered or available in your country. We can help facilitate the supply of Sotyktu® through legal channels.

For more information, please contact +1-647-818-4196 or email us at info@urgentmeds.in.